# Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

> **NCT04636632** · PHASE1 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 100 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** fosaprepitant

## Key facts

- **NCT ID:** NCT04636632
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-24
- **Primary completion:** 2022-11-04
- **Final completion:** 2022-11-04
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04636632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04636632, "Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04636632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*